Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN4461
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN4461 is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals that targets coagulation Factor XI (FXI). It is designed to prevent venous thromboembolism (VTE) by inhibiting the intrinsic pathway of the coagulation cascade. Factor XI is a key component in the amplification of thrombin generation; however, its role in normal hemostasis is relatively limited compared to its role in pathological thrombosis. Consequently, inhibiting FXI is hypothesized to provide effective anticoagulation with a significantly lower risk of clinical bleeding compared to traditional therapies like heparin or direct oral anticoagulants (DOACs). REGN4461 has been evaluated in Phase 2 clinical trials for the prevention of VTE in patients undergoing major orthopedic surgery, such as total knee arthroplasty.
- Other names
- factor XI monoclonal antibodyFXI antibodyanti-FXI monoclonal antibody
02
Targets
LEPR (Leptin receptor)F11 (Coagulation Factor XI)
Beyond the preview
Go deeper on REGN4461.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN4461.